Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.US based VBI Vaccines has acquired French biotechnology firm Epixis, which develops eVLP platform technology for a new generation of virus-like particle (VLP) vaccines.
Subscribe to our email newsletter
The acquisition allows VBI to develop its own VLP-based vaccines by leveraging its suite of thermostable vaccine formulation technologies.
The terms of the deal were not disclosed.
VBI president and CEO Jeff Baxter said the acquisition enables VBI to strategically build upon their pipeline of vaccine delivery technologies and advance the development of an extremely promising VLP platform.